Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Agilent TechnologiesMIL:1A 71 Return-on-Tangible-Equity is 64.27% as of Apr. 2026, which is 47% below its 10-year median of 120.29. GuruFocus rates MIL:1A with a GF Score™ of 71/100 and a GF Value™ of €127.82 (Fairly Valued). The stock has 1 warning sign investors should review. Among 193 Medical Diagnostics & Research companies, Agilent Technologies ranks better than 84.46% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Agilent Technologies's annualized net income for the quarter that ended in Apr. 2026 was €1,159 Mil. Agilent Technologies's average shareholder tangible equity for the quarter that ended in Apr. 2026 was €1,804 Mil. Therefore, Agilent Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Apr. 2026 was 64.27%.
The historical rank and industry rank for Agilent Technologies's Return-on-Tangible-Equity or its related term are showing as below:
MIL:1A'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 21.31 Med: 120.29 Max: 294.67
Current: 81.78
During the past 13 years, Agilent Technologies's highest Return-on-Tangible-Equity was 294.67%. The lowest was 21.31%. And the median was 120.29%.
MIL:1A's Return-on-Tangible-Equity is ranked better than 84.46% of 193
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.33
vs MIL:1A: 81.78
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Agilent Technologies Return-on-Tangible-Equity Related Terms
Agilent Technologies Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Agilent Technologies's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1A vs NTRA, WAT, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Agilent Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agilent Technologies Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Agilent Technologies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Apr. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 64.27% mean?
Agilent Technologies (MIL:1A) has a Return-on-Tangible-Equity of 64.27% as of Apr. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Agilent Technologies and its competitors. This is 47% below median its historical median of 120.29. Over the past decade, Agilent Technologies' Return-on-Tangible-Equity has ranged from 21.31 to 294.67. According to the industry distribution chart, Agilent Technologies ranks #30 out of 193 companies in the Medical Diagnostics & Research industry, placing it in the top 15.5%.
Is Agilent Technologies' Return-on-Tangible-Equity too high?
Agilent Technologies' current Return-on-Tangible-Equity of 64.27% is 47% below median its 10-year median of 120.29. Over the past 10 years, this metric has ranged from a low of 21.31 to a high of 294.67. Based on the distribution chart, Agilent Technologies ranks #30 out of 193 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Agilent Technologies has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' Return-on-Tangible-Equity compare to NTRA and WAT?
According to the Medical Diagnostics & Research industry distribution chart, Agilent Technologies ranks #30 out of 193 companies for Return-on-Tangible-Equity. This places Agilent Technologies in the top 16% of its industry — outperforming the majority of peers. Historically, Agilent Technologies' own Return-on-Tangible-Equity has ranged from 21.31 to 294.67 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Agilent Technologies and its competitors. Agilent Technologies's current Return-on-Tangible-Equity is 64.27%, which is 47% below median its own 10-year median of 120.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (MIL:1A) is currently considered Fairly Valued. The stock's GF Value™ is €127.82, compared to a current price of €117.45 — trading 8.1% below its estimated fair value. The current Return-on-Tangible-Equity is 64.27%, which is 47% below median its 10-year median of 120.29. Agilent Technologies' overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Agilent Technologies (MIL:1A), the current Return-on-Tangible-Equity is 64.27% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agilent Technologies (MIL:1A) Overvalued in 2026?
Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued.
The current stock price of €117.45 is trading 8.1% below its estimated GF Value™ of €127.82.
GuruFocus considers Agilent Technologies to be Fairly Valued.
Key valuation signals for MIL:1A:
Return-on-Tangible-Equity: 64.27% (47% below median its 10-year median of 120.29)
GF Value™: €127.82 vs. price of €117.45 (8.1% below fair value)
No single metric tells the full story. See the MIL:1A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
71GF Score
Get the complete analysis for MIL:1A
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1A has been successfully added to your 
